Sematilide hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526330

CAS#: 101526-62-9 (HCl)

Description: Sematilide, also known as CK-1752, is a class III antiarrhythmic. It is a selective delayed rectifier K+ current (IKr) channel blocker. It inhibits rapidly activating Ik in guinea pig atrial myocytes, resulting in the prolongation of action potential duration and refractoriness.

Chemical Structure

Sematilide hydrochloride
CAS# 101526-62-9 (HCl)

Theoretical Analysis

MedKoo Cat#: 526330
Name: Sematilide hydrochloride
CAS#: 101526-62-9 (HCl)
Chemical Formula: C14H24ClN3O3S
Exact Mass:
Molecular Weight: 349.87
Elemental Analysis: C, 48.06; H, 6.91; Cl, 10.13; N, 12.01; O, 13.72; S, 9.16

Price and Availability

Size Price Availability Quantity
5.0mg USD 90.0 Ready to ship
10.0mg USD 150.0 Ready to ship
25.0mg USD 250.0 Ready to ship
50.0mg USD 450.0 Ready to ship
100.0mg USD 750.0 Ready to ship
200.0mg USD 1250.0 Ready to ship
500.0mg USD 2650.0 Ready to ship
Bulk inquiry

Related CAS #: 101526-83-4 (free base)   101526-62-9 (HCl)    

Synonym: Sematilide hydrochloride; Sematilide HCl; Sematilide hydrochloride; Sematilide; CK-1752A; CK1752A; CK 1752A; CK-1752; CK1752; CK 1752.

IUPAC/Chemical Name: Benzamide, N-(2-(diethylamino)ethyl)-4-((methylsulfonyl)amino)-, monohydrochloride


InChi Code: InChI=1S/C14H23N3O3S.ClH/c1-4-17(5-2)11-10-15-14(18)12-6-8-13(9-7-12)16-21(3,19)20;/h6-9,16H,4-5,10-11H2,1-3H3,(H,15,18);1H


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
DMF 12.0 34.3
DMSO 12.0 34.3
Ethanol 3.0 8.6
PBS (pH 7.2) 5.0 14.3

Preparing Stock Solutions

The following data is based on the product molecular weight 349.87 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Kugiyama K, Hashimoto K. Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. Circ J. 2002 Aug;66(8):758-62. PubMed PMID: 12197602.

2: Sugiyama A, Hashimoto K. Effects of a typical I(Kr) channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Jpn J Pharmacol. 2002 Apr;88(4):414-21. PubMed PMID: 12046984.

3: Sematilide. CK 1752, CK 1752A, ZK 110516. Drugs R D. 1999 Apr;1(4):322-6. PubMed PMID: 10566054.

4: Ishii Y, Muraki K, Kurihara A, Imaizumi Y, Watanabe M. Effects of sematilide, a novel class III antiarrhythmic agent, on membrane currents in rabbit atrial myocytes. Eur J Pharmacol. 1997 Jul 23;331(2-3):295-302. PubMed PMID: 9274992.

5: Takai H, Sato R, Katori R. Sematilide blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes. Gen Pharmacol. 1997 May;28(5):665-70. PubMed PMID: 9184799.

6: Beatch GN, Davis DR, Laganière S, Williams BA. Rate-dependent effects of sematilide on ventricular monophasic action potential duration and delayed rectifier K+ current in rabbits. J Cardiovasc Pharmacol. 1996 Nov;28(5):618-30. PubMed PMID: 8945674.

7: Chen J, Komori S, Li B, Tamura K, Hashimoto K. IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats. Br J Pharmacol. 1996 Nov;119(5):937-42. PubMed PMID: 8922743; PubMed Central PMCID: PMC1915953.

8: Ishii Y, Muraki K, Kurihara A, Imaizumi Y, Watanabe M. Effects of sematilide, a novel class III antiarrhythmic agent, on delayed rectifier K+ current in guinea pig atrial myocytes. Jpn J Pharmacol. 1996 Aug;71(4):361-5. PubMed PMID: 8886937.

9: Xue YX, Eto K, Akie Y, Hashimoto K. Antiarrhythmic and proarrhythmic effects of sematilide in canine ventricular arrhythmia models. Jpn J Pharmacol. 1996 Feb;70(2):129-38. PubMed PMID: 8866750.

10: Shi J, Ripley E, Gehr TW, Sica DA, Dandekar KA, Hinderling PH. Pharmacokinetics of sematilide in renal failure. J Clin Pharmacol. 1996 Feb;36(2):131-43. PubMed PMID: 8852389.

11: Yamada A, Motomura S, Hashimoto K. Comparison of direct negative chronotropic and positive inotropic effects of sematilide to those of E-4031 and MS-551 and the reverse frequency-dependent prolongation of cardiac refractoriness of sematilide. J Cardiovasc Pharmacol. 1996 Jan;27(1):159-66. PubMed PMID: 8656651.

12: Stambler BS, Gottlieb SS, Singh BN, Ramanathan KB, Ogilby JD, Ellenbogen KA. Hemodynamic effects of intravenous sematilide in patients with congestive heart failure: a class III antiarrhythmic agent without cardiodepressant effects. J Am Coll Cardiol. 1995 Dec;26(7):1679-84. PubMed PMID: 7594103.

13: Shi J, Lasser T, Koziol T, Hinderling PH. Kinetics and dynamics of sematilide. Ther Drug Monit. 1995 Oct;17(5):437-44. PubMed PMID: 8585104.

14: Ishii Y, Muraki K, Kurihara A, Imaizumi Y, Watanabe M. Effects of sematilide, a novel class III antiarrhythmic agent, on action potential in guinea pig atrium. Jpn J Pharmacol. 1995 Jun;68(2):175-82. PubMed PMID: 7563974.

15: Cui G, Sen L, Sager P, Uppal P, Singh BN. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol. 1994 Nov 1;74(9):896-900. PubMed PMID: 7526675.

16: Laganière S, Goernert L, Beatch G. High-performance liquid chromatographic assay for sematilide in plasma using solid-phase extraction microcolumn technology. J Chromatogr B Biomed Appl. 1994 Oct 3;660(1):191-5. PubMed PMID: 7858714.

17: Sawanobori T, Adaniya H, Namiki T, Hiraoka M. Rate-dependent effects of sematilide on action potential duration in isolated guinea pig ventricular myocytes. J Pharmacol Exp Ther. 1994 Oct;271(1):302-10. PubMed PMID: 7965729.

18: Sager PT, Follmer C, Uppal P, Pruitt C, Godfrey R. The effects of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of amiodarone and sematilide in humans. Circulation. 1994 Oct;90(4):1811-9. PubMed PMID: 7923666.

19: Sager PT, Nademanee K, Antimisiaris M, Pacifico A, Pruitt C, Godfrey R, Singh BN. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans. Circulation. 1993 Sep;88(3):1072-82. PubMed PMID: 8353869.

20: Hinderling PH, Dilea C, Koziol T, Millington G. Comparative kinetics of sematilide in four species. Drug Metab Dispos. 1993 Jul-Aug;21(4):662-9. PubMed PMID: 8104126.